Traders should monitor for potential short-term downward pressure due to share dilution, though the capital strengthens the balance sheet for upcoming commercial and clinical milestones. The use of proceeds supports long-term value creation if barzolvolimab gains approval and achieves market uptake.
Price Chart
Executive Summary
Celldex Therapeutics priced a public offering of 10,345,000 shares at $29.00 per share, raising approximately $300 million in gross proceeds. The company may sell an additional 1,551,750 shares via an underwriter option, and plans to use the funds for commercial readiness of barzolvolimab, clinical development, and general corporate purposes.
Key Financial Metrics
Key Facts
- Celldex is offering 10,345,000 shares at $29.00 per share.
- Gross proceeds expected: ~$300 million (excluding underwriter option).
- Underwriters have a 30-day option to purchase up to 1,551,750 additional shares.
- Proceeds will fund commercial launch of barzolvolimab (if approved), clinical development, platform expansion, and general corporate needs.
- Offering expected to close April 6, 2026, subject to customary conditions.
Financial Impact
$300 million gross proceeds, with potential for $44.5 million more if underwriters fully exercise their option (total ~$344.5M). Dilution estimated at ~10.5% of current market cap ($2.1B).
Risk Factors
- Dilution from new share issuance may pressure stock price near closing.
- Forward-looking statements carry uncertainty around future commercial and clinical outcomes.
- Market conditions could affect final execution if underwriters exercise their option.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3267105 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 14, 2026 15w ago | Press Release | $32.12 $38.53 | ▼ −19.96% | ▼ −20.71% | $32.07 (+0.16%) |
Jun 14, 2026 15w ago | Press Release | $32.12 $38.53 | ▲ +19.96% | ▲ +20.71% | $32.07 (−0.16%) |
Jun 11, 2026 16w ago | Institutional Cluster | $29.96 $38.98 | ▲ +30.11% | ▲ +28.22% | $32.07 (+7.04%) |
Jun 10, 2026 16w ago | Press Release | $29.96 $38.98 | ▲ +30.11% | ▲ +28.22% | $32.07 (+7.04%) |
May 7, 2026 21w ago | 8-K | $33.97 $28.62 | ▼ −15.75% | ▼ −15.77% | $32.07 (−5.59%) |
May 7, 2026 21w ago | Press Release | $33.97 $28.62 | ▼ −15.75% | ▼ −15.77% | $32.07 (−5.59%) |
Apr 6, 2026 25w ago | Press Release | $31.37 $32.77 | ▲ +4.46% | ▼ −4.52% | $32.07 (+2.23%) |
Apr 2, 2026 26w ago | Press Release | $31.06 $32.88 | ▲ +5.86% | ▼ −4.02% | $32.07 (+3.25%) |
Apr 1, 2026 26w ago | 424B5 | $31.06 $32.88 | ▲ +5.86% | ▼ −4.02% | $32.07 (+3.25%) |
Apr 1, 2026 26w ago | Press Release | $31.06 $32.88 | ▲ +5.86% | ▼ −4.02% | $32.07 (+3.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access